This study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 10(9)/L) for a median of 12 days (2-41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6-26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.
Pagano, L., Fianchi, L., Fanci, R., Candoni, A., Caira, M., Posteraro, B., Morselli, M., Valentini, C., Farina, G., Mitra, M., Offidani, M., Sanguinetti, M., Tosti, M., Nosari, A., Leone, G., Viale, P., Caspofungin for the treatment of candidaemia in patients with haematological malignancies, <<CLINICAL MICROBIOLOGY AND INFECTION>>, 2010; 16 (3): 298-301. [doi:10.1111/j.1469-0691.2009.02832.x] [http://hdl.handle.net/10807/8041]
Caspofungin for the treatment of candidaemia in patients with haematological malignancies
Pagano, Livio;Fianchi, Luana;Caira, Morena;Posteraro, Brunella;Farina, Giuliana;Sanguinetti, Maurizio;Leone, Giuseppe;
2010
Abstract
This study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 10(9)/L) for a median of 12 days (2-41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6-26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
